Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Cesarone MR, Hu S, Belcaro G, et al
Retatrutide (CAS 2381089-83-2) is a triple-agonist peptide that engages three receptors simultaneously the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor making it one of the most-studied multi-receptor metabolic peptides currently in the research literature
The REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) trial assessed the effect of dulaglutide, a GLP-1RA, vs placebo added to standard of care in 9901 subjects with T2D
Diabetes 53(5):11871194 Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U et al (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
When activated, they act like an emergency brake at the end of the meal, flooding the brain with GLP-1 to send the message to stop eating
A further four weeks will be used for post-treatment safety monitoring
US$ 24.06
US$ 22.83
US$ 28.16
